Valcyte is indicated for the induction and maintenance treatment of cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS). Valcyte is indicated for the prevention of CMV disease in CMV-negative adults and children (aged from birth to 18 years) who have received a solid organ transplant from a CMV-positive donor.
Cymevene is indicated in adults and adolescents ≥ 12 years of age for the: - treatment of cytomegalovirus (CMV) disease in immunocompromised patients; - prevention of CMV disease using pre-emptive therapy in patients with drug-induced immunosuppression (for example following organ transplantation or cancer chemotherapy). Cymevene is also indicated from birth for the: - prevention of CMV disease using universal prophylaxis in patients with drug-induced immunosuppression (for example following organ transplantation or cancer chemotherapy). Consideration should be given to official guidance on the appropriate use of antiviral agents.
Mavenclad (cladribine tablets) from Merck KGaA, is now indicated for the treatment of adult patients with relapsing forms of Multiple Sclerosis (MS) with active disease as defined by clinical or imaging features following approval by the MHRA, meaning more newly diagnosed patients could be eligible for treatment earlier in their disease course.